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Chordomas are rare bone tumors with few therapeutic options. Here we show, using whole-
exome and genome sequencing within a precision oncology program, that advanced chor-
domas (n= 11) may be characterized by genomic patterns indicative of defective homologous
recombination (HR) DNA repair and alterations affecting HR-related genes, including, for
example, deletions and pathogenic germline variants of BRCA2, NBN, and CHEK2. A muta-
tional signature associated with HR deficiency was significantly enriched in 72.7% of samples
and co-occurred with genomic instability. The poly(ADP-ribose) polymerase (PARP) inhibitor
olaparib, which is preferentially toxic to HR-incompetent cells, led to prolonged clinical
benefit in a patient with refractory chordoma, and whole-genome analysis at progression
revealed a PARP1 p.T910A mutation predicted to disrupt the autoinhibitory PARP1 helical
domain. These findings uncover a therapeutic opportunity in chordoma that warrants further
exploration, and provide insight into the mechanisms underlying PARP inhibitor resistance.
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Chordomas are rare tumors of the axial skeleton and skullbase that arise from remnants of the embryonic noto-chord, a transient midline structure that guides vertebral
development, provides patterning information for surrounding
tissues, and ultimately regresses to form the nucleus pulposus in
the intervertebral disc1. First-line treatment of chordoma is based
on surgical resection and radiotherapy. However, due to the
proximity of most chordomas to vital structures, especially at the
skull base, local control is rarely achieved, resulting in a recur-
rence rate greater than 50%. Furthermore, locoregional or distant
metastases occur in 30–40% of cases2. Systemic treatment of
advanced disease is exceedingly difficult as chordomas are gen-
erally resistant to conventional chemotherapy, and no drugs are
approved for this indication. Several targeted agents directed
against PDGFRA/B, EGFR, or mTORC1 have yielded encoura-
ging rates of disease stabilization, although objective responses are
rare and the often slow growth rate of chordomas needs to be
taken into account2–4. Blockade of brachyury, a notochordal
transcription factor that drives chordoma development and is not
expressed in most normal adult tissues5, represents, in principle,
a promising strategy to selectively target chordoma cells. How-
ever, transcription factors are notoriously difficult to inhibit with
small molecules. Thus, there remains an urgent need for novel
therapeutic strategies to improve clinical outcomes in chordoma
patients.
Whether insights into the genomic landscape of sporadic
chordoma might provide new entry points for targeted therapies
remains incompletely understood. Earlier studies employing
microarray technologies, fluorescence in situ hybridization,
quantitative PCR, and targeted sequencing of select cancer genes
showed that chordomas are primarily characterized by non-
random DNA copy number losses across the genome, frequently
involving CDKN2A, PTEN, and chromatin regulatory genes
such as SMARCB1 as potentially actionable alterations, as well as
recurrent gains of the TBXT gene encoding brachyury6–9. More
recently, a survey of single-nucleotide variants (SNVs), small
insertions/deletions (indels), structural rearrangements, and copy
number changes using a combination of whole-exome sequencing
(WES), whole-genome-sequencing (WGS), and targeted sequen-
cing identified recurrent alterations in additional loci not pre-
viously implicated in chordoma, such as ARID1A, encoding
a subunit of the SWI/SNF chromatin remodeling complex, and
LYST, whose protein product regulates lysosomal trafficking10.
In this study, we have used WES and WGS to inform clinical
decision making in patients with advanced chordoma who
have exhausted standard treatment options. We observed that
advanced chordomas may frequently harbor molecular alterations
associated with impaired DNA repair via homologous recombi-
nation (HR) as potentially actionable genetic vulnerabilities.
These results prompted experimental treatment with a poly
(ADP-ribose) polymerase (PARP) inhibitor in a patient whose
tumor was refractory to irradiation and medical therapy, which
led to a prolonged response and enabled the discovery of muta-
tional destabilization of the autoinhibitory PARP1 alpha-helical
domain (HD) as an yet unrecognized mechanism underlying
acquired PARP inhibitor resistance.
Results
WES and WGS of chordoma within a precision oncology
program. To identify therapeutically tractable molecular lesions,
we performed WES (n= 9) and WGS (n= 2) of tumor tissue and
matched blood from 11 patients (age, 27–72 years) with locally
advanced and/or metastatic chordoma who were enrolled in the
MASTER (Molecularly Aided Stratification for Tumor Eradica-
tion Research) program, a registry trial for younger adults with
advanced cancer across all histologies and patients with rare
tumors11. All patients had previously received radiotherapy to the
primary tumor site, following surgical resection in nine of 11
cases. Systemic treatment had been administered in six of 11 cases
(imatinib, n= 4; imatinib/sirolimus, n= 1; imatinib followed by
sunitinib, imatinib/everolimus, and erlotinib/bevacizumab, n= 1;
doxorubicin and ifosfamide, n= 1). All patients had progressive
disease prior to molecular analysis. Detailed clinical information
is provided in Supplementary Table 1. Sequencing parameters are
provided in Supplementary Tables 2 and 3. Consistent with a
recent analysis of the genomic landscape of sporadic chordoma10,
tumors had a modest burden of non-synonymous somatic
mutations (Supplementary Data 1), ranking them among cancers
such as prostate adenocarcinoma and neuroblastoma12. In con-
trast, analysis of DNA copy number profiles showed high num-
bers of structural variants greater than 10 million base pairs
(mbp) in size in the majority of cases (Fig. 1a, b and Supple-
mentary Fig. 1). Recurrent deletions of chromosome 9p21.3
encompassing the cell cycle regulatory genes CDKN2A/B were
found in all tumors, corroborating previous karyotypic and
molecular cytogenetic findings that led to the notion that chor-
domas might be amenable to CDK4/6 inhibition13, a hypothesis
that is being explored in a phase 2 clinical trial (ClinicalTrials.gov
Identifier NCT03110744).
Alterations of HR DNA repair genes in chordoma. Given that
structural rearrangements may be caused by defective repair of
DNA double-strand breaks via HR14, we explored the possibility
that HR deficiency contributes to chordoma development. We
first compiled a list of 23 candidate HR genes. Specifically, we
selected 12 genes that were assessed as a biomarker to stratify
patients with castration-resistant prostate cancer for olaparib
treatment in a recent phase 2 clinical trial and 11 additional
genes reported to be involved in DNA damage repair or sensi-
tivity to PARP inhibition (Supplementary Table 4)15. Examina-
tion of individual loci revealed that two patients with no previous
history of cancer had pathogenic (Class 5 according to the
American College of Medical Genetics and Genomics [ACMG]
classification system; https://www.ncbi.nlm.nih.gov/clinvar)
germline variants in established DNA repair genes (Supplemen-
tary Data 1). A heterozygous germline BRCA2 frameshift muta-
tion (p.T3085fs*26) was accompanied by somatic deletion of the
wild-type allele and co-occurred with biallelic somatic PTEN
alterations (p.R233X mutation and loss of heterozygosity) in
patient Chord_03. A heterozygous germline NBN frameshift
mutation (p.K219Nfs*16) was accompanied by somatic deletion
of the wild-type allele in patient Chord_06. In addition, patient
Chord_01 had a heterozygous germline CHEK2 missense variant
(p.R145W) that leads to destabilization of CHEK2 and failure of
the S-phase checkpoint and has been classified as likely patho-
genic (ACMG Class 4)16. This variant was accompanied by
somatic deletion of the CHEK2 wild-type allele and co-occurred
with biallelic somatic PTEN alterations (heterozygous p.G251V
mutation and deletion of the wild-type allele). Three patients had
germline variants of uncertain significance (ACMG Class 3) in
FANCG, RAD51B, and RPA1, respectively, whose allele fre-
quencies were not increased in the tumor compared with the
normal control sample.
Genomic imprints of defective HR DNA repair in chordoma.
In addition to structural rearrangements and alterations of indivi-
dual HR DNA repair genes, we detected seven known mutational
signatures (http://cancer.sanger.ac.uk/cosmic/signatures)17. Sig-
nature Alexandrov-COSMIC 3 (AC3), associated with defective
HR, was found in all samples, and the 95% confidence interval of
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the exposure to AC3 excluded zero in eight of 11 samples (72.7%;
Fig. 1c). Comparison of the signatures identified in our cohort to
a background of 7042 cancer samples (WGS, n= 507; WES, n=
6,535)17 showed significant enrichment of AC3 (P= 4.52 × 10–6).
Signature AC3 co-occurred with extensive genomic instability, as
illustrated by HR deficiency (HRD) scores and high numbers of
large-scale state transitions (LSTs; Fig. 1d)18.
Actionability of defective HR DNA repair in chordoma. Patient
Chord_05, while not meeting traditional criteria for defective HR
such as biallelic inactivation of BRCA1/2, showed an exceptional
exposure to the mutational signature AC3 and a high degree
of genomic instability (Fig. 1a–d). This patient, a 57-year-old
man, had been diagnosed with inoperable sacrococcygeal chor-
doma 80 months prior to enrollment in the MASTER program
and underwent proton radiation therapy. Following progression
68 months after first diagnosis, the tumor proved refractory
to repeat irradiation and, after initial stabilization, to systemic
treatment with the tyrosine kinase inhibitor imatinib, as evi-
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symptoms such as pain, incontinence, and walking disability.
Given that defects in HR impair the repair of DNA double-strand
breaks caused by chemotherapeutic agents such as cisplatin,
and are synthetic lethal to inhibition of PARP19, the tumor’s
genomic profile was considered actionable and off-label therapy
with the PARP inhibitor olaparib at 800 mg daily was initiated.
Besides mild neutropenia and anemia (Common Terminology
Criteria for Adverse Events Grade 1–2), treatment was well tol-
erated, tumor symptoms gradually decreased after 2 months, and
the patient was ambulatory again. Magnetic resonance imaging
(MRI) after 5 months of treatment demonstrated that disease
progression was halted, with the tumor showing signs of necrosis,
partial volume shrinkage, and decreased cellularity (Fig. 1e).
Olaparib resistance due to impaired PARP1 autoinhibition.
Regrettably, follow-up MRI of the pelvis after 10 months of
olaparib treatment showed progressive disease (Fig. 2a), which
was reflected by increased pain in the sacrum radiating to the
perineal region and the thighs as well as recurrent incontinence.
To search for genetic mechanisms underlying the acquired
resistance to PARP inhibition, a repeat biopsy from a progressive
region of the tumor (Chord_05R) was subjected to WGS.
This analysis revealed a highly rearranged DNA copy number
profile with multiple structural and numerical changes distributed
across the genome, including highly complex structural rearran-
gements of chromosomes 6 and 15 (Supplementary Fig. 2). In
addition, we identified an increase in the number of coding non-
synonymous mutations (SNVs, 60 versus 40; indels, 14 versus 4)
compared with the exome sequence obtained before olaparib
treatment (Supplementary Data 1). Among the newly gained
variants were a TP53 frameshift mutation (A83fs; mutant allele
frequency, 55%) and a PARP1 missense variant (p.T910A; mutant
allele frequency, 28%) whose presence was confirmed by
Sanger sequencing (Fig. 2b). Analysis of the variant allele frac-
tions from the two samples using a look-up procedure demon-
strated that the variants private to either specimen outnumbered
those shared by both, indicating that the separation of the
clones active before and after olaparib treatment occurred early
in the growth history of this tumor (Supplementary Fig. 3).
To investigate whether the PARP1 p.T910A mutation provided
a mechanistic explanation for the secondary failure of olaparib
treatment, thereby validating PARP1 as a therapeutic target in
this tumor, we performed protein structure modeling analyses.
Threonine 910 is located in a loop region adjacent to the
enzymatic site that is part of the interface between the signature
ADP-ribosyl transferase (ART) fold and the regulatory HD of
the PARP1 catalytic domain (Fig. 2c, d). However, similar to
mutations of residues Y848 and A925 in the ART domain that
were recently identified in a CRISPR-based mutagenesis screen
for PARP inhibitor resistance alleles20, the p.T910A variant does
not appear to have a direct effect on olaparib binding as T910
is not part of the NAD+ binding pocket and does not contact the
drug. In addition to binding the catalytic site, thereby blocking
NAD+ access and poly(ADP-ribose) formation, olaparib is
thought to inhibit PARP1 function through at least two additional
mechanisms. First, it traps PARP1 on DNA single-strand breaks
via conformational changes in the active site loop, resulting in
obstructed replication forks that require HR to be resolved20–22.
Second, olaparib favors the inactive conformation of PARP1 by
stabilizing the HD, which is critical for allosteric autoinhibitory
interactions as illustrated by the constitutive activity of a PARP1
mutant lacking the HD, even in the presence of olaparib bound
to the catalytic pocket23,24. To gain insight into the functional
consequences of the p.T910A variant, we performed energy
calculations25, which predict the stabilizing or destabilizing effect
of a mutation as negative or positive difference in free energy
(ddG) between the mutant and wild-type proteins. The p.T910A
variant was overall predicted to destabilize the structure of the
PARP1 catalytic domain (Supplementary Table 5). However,
calculations employing a constitutively active PARP1 structure
lacking the autoinhibitory HD23 indicated a weak destabilizing
effect (ddG= 0.233 Rosetta Energy Units [REU]; Fig. 2e),
whereas predictions on the ART domain and the HD of the
PARP1-DNA complex structure yielded a much stronger
destabilizing effect (ddG= 1.865 REU; Fig. 2d), possibly due to
different local packing of the T910 side chain and/or propagation
of the perturbation to the interaction interface with the HD.
This indicates that the p.T910A mutation acts allosterically to
destabilize HD-mediated autoinhibition, favoring an active-like
conformation that overrides PARP1 inhibition by olaparib. In
line with experimental data obtained in the context of HD-
deficient PARP123, our simulations suggest that this effect will be
independent of the presence of olaparib as there was only a slight
difference in free energy (ddG= 0.233 REU; Fig. 2e) following
binding of the inhibitor.
Discussion
Our data suggest that advanced and extensively pretreated chor-
domas are recurrently characterized by genomic alterations asso-
ciated with defective DNA repair via the HR pathway, including
biallelic germline and somatic mutations of individual genes
involved in this process, enrichment of a specific mutational sig-
nature induced by HR deficiency, and increased genomic instability.
Interestingly, only three of 11 patients carried genetic alterations
Fig. 1 HR deficiency as clinically actionable feature in chordoma. a Copy number plot of patient Chord_05 showing chromosomal coordinates based on
WES data (horizontal axis) and the log2 ratio of copy number changes (vertical axis). Red and black regions indicate different chromosomes. b CNA profile
of patient Chord_05. Segment-wise total copy number counts after correction for TCC and ploidy are shown. c Contribution of mutational signatures
(absolute exposures) to the overall SNV load in chordoma patients. Each bar represents the number of SNVs explained by the respective mutational
signature in an individual tumor. Error bars represent 95% confidence intervals. Exposures for tumors analyzed by WES are displayed on the left. Exposures
for tumors analyzed by WGS are displayed on the right. AC1 clock-like, spontaneous deamination; AC2 and AC13 altered APOBEC activity; AC3 defective
HR; AC6 defective DNA mismatch repair; AC7 ultraviolet light exposure; AC10 altered POLE activity. d Scatter plot of measures of genomic instability
(sum of HRD score and number of LSTs; vertical axis) versus exposures to signature AC3 (horizontal axis). To include both WES and WGS data, exposures
to AC3 were normalized to the size of the target capture. e Therapeutic targeting of defective HR in patient Chord_05. T1-weighted, fat-saturated, post-
contrast MRI at baseline 1 (left panel), after 6 months of imatinib therapy (progressive disease, baseline 2 for further follow-up; middle panel), and after
5 months of olaparib therapy (stable disease compared to baseline 2; right panel). A biopsy for WES was taken at progression (middle panel). The main
bulk of the sacrococycgeal chordoma is located right to the midline with infiltration of the pelvis and the gluteal muscles (white rectangles). Corresponding
apparent diffusion coefficient (ADC) maps derived from diffusion-weighted imaging of the tumor area are shown in the top right corner of each panel.
Compared to baseline 2, a reduction of tumor bulk, especially the intrapelvic component, and increased necrosis, as indicated by new areas with lack of
contrast enhancement, were seen. An increase in ADC from 1030 mm2s−1 to 1352 mm2s−1 between both time points indicates a reduction in cellularity
(yellow arrows)
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that would meet traditional criteria for HR deficiency (biallelic
inactivation of BRCA2, NBN, and CHEK2, respectively), which
highlights the need to develop novel tools for identifying tumors
with functional defects similar to those associated with BRCA1/2
inactivation. The potential of compound genomic measures in this
regard is illustrated by our findings in patient Chord_05 who
showed a striking exposure to signature AC3 and a high degree of
genomic instability, as evidenced by an elevated HRD score and a
high number of LSTs. Although the underlying mutations were not
identified unambiguously, these features by themselves formed the
basis for successful therapy with single-agent olaparib, and acquired
resistance was associated with a newly gained PARP1 mutation that
is predicted to restore enzymatic activity in the presence of drug,



































Fig. 2 Acquired resistance to olaparib treatment in chordoma. a T1-weighted, fat-saturated, post-contrast MRI after 7 months (stable disease; left panel)
and 10 months (progressive disease; right panel) of olaparib therapy. A biopsy for WGS was taken at progression (right panel). b Missense mutation in
PARP1 exon 20 detected by Sanger sequencing. Nucleotide (arrow) and amino acid substitutions are given next to the chromatograms. Sequence
numbering is according to NCBI Reference Sequences NM_001618 and NP_001609. c Structure of p.T910A-mutant PARP1 bound to DNA (PDB ID:
4DQY). Side chains of amino acids whose mutation has been linked to PARP1 inhibitor resistance (T910, this study; R591, H742, Y848, and A925, ref. 19)
are represented as spheres. WGR tryptophan-glycine-arginine-rich domain; ZnF1 zinc-finger domain 1; ZnF3 zinc-finger domain 3. d Detail view of the
p.T910A mutation site in the PARP1-DNA complex structure (PDB ID: 4DQY). Threonine 910 and amino acids whose side chains are displaced according
to energy calculations (cut-off, 0.05 Ǻ) are represented as red and olive sticks and surfaces, respectively. e Detail view of the p.T910A mutation site in
the structure of constitutively active PARP1 (PDB ID: 5DS3) in complex with olaparib (represented as gray sticks and surface)
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09633-9 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1635 | https://doi.org/10.1038/s41467-019-09633-9 | www.nature.com/naturecommunications 5
note, most patients in our study also exhibited monoallelic HR gene
deletions. However, the question of whether heterozygous loss of
multiple HR genes in the context of structural rearrangements leads
to, or is reflective of, HR deficiency, and how pathogenic variants in
other genes may contribute to chordoma development cannot be
answered by our study.
The observed prevalence of an HR deficiency footprint in
advanced chordomas, which is reminiscent of the genomic
features of breast, ovarian, and prostate cancer in which HR
deficiency has emerged as a therapeutic liability15,19, provides
a rationale for genomics-guided therapy using agents, either
alone or in combination, that are preferentially toxic to HR-
incompetent cells, such as PARP inhibitors, platinum derivatives,
or trabectedin. Furthermore, given recent preclinical reports on
the efficacy of immune checkpoint blockade in HR-deficient
tumors, the results presented herein and the finding of PD-1
and PD-L1 expression in the chordoma microenvironment may
warrant clinical trials of immune checkpoint inhibitors in
chordoma26,27. Of note, all tumors had been exposed to radio-
therapy prior to molecular analysis, raising the interesting
possibility that this treatment may have shaped their genomic
profiles and associated therapeutic vulnerabilities. Therefore,
even though the imprint of ionizing radiation in cancer is not
well understood28 and previous microarray analyses that
included radiation-naïve cases indicate that multiple DNA copy
number alterations are an intrinsic feature of chordoma8, future
studies should address whether radiotherapy or other extrinsic
conditions, such as exposure to cytotoxic drugs, might result
in conditional synthetic cytotoxicity that can be exploited
therapeutically29.
In addition to identifying PARP inhibition as a molecularly
guided strategy to target refractory chordomas, our data also
provide insight into the mechanisms underlying acquired resis-
tance to this treatment modality. While previous in vitro studies
uncovered that the selective pressure provided by PARP inhibi-
tors can lead to restoration of HR via revertant mutations in
BRCA1/2 or RAD51C/D, inactivation of 53BP1 or REV7, and loss
of PARP1 expression30, the importance of PARP1 mutations has
only recently emerged based on forward genetic screens and the
observation of a p.R591C variant in the PARP1 tryptophan-
glycine-arginine-rich domain in an ovarian cancer patient who
showed de novo resistance to olaparib20. We now expand these
data by reporting the first example of a secondary mutation,
p.T910A, in the PARP1 HD that occurred in a patient whose
disease progressed after 10 months of olaparib treatment, and
protein structure modeling analyses supported a mechanism of
olaparib resistance in which the p.T910A allele restores PARP1
activity in the presence of the drug by disabling HD-mediated
autoinhibition. From a therapeutic perspective, it will be parti-
cularly interesting to investigate whether other PARP inhibitors
currently tested in clinical trials, such as rucaparib and talazo-
parib, may overcome p.T910A-mediated resistance as our ana-
lysis of the mutation’s impact on the ART domain-HD interface
demonstrated that these drugs have additional contacts with
residues in the HD (e.g., Q759, E763, and D766) when compared
to olaparib (Supplementary Fig. 4), which might increase their
capacity to stabilize the autoinhibited conformation.
In summary, our study has uncovered a biological feature
of advanced chordoma that represents an immediately actionable
therapeutic target and provides a rationale for genomics-guided
clinical trials of pharmacologic PARP inhibition in this intract-
able tumor entity. More broadly, our findings illustrate that the
concept of “BRCAness” as clinically actionable genomic feature
extends beyond common epithelial cancers, and further our
understanding of the mechanisms underlying acquired resistance
to this important class of targeted cancer therapeutics.
Methods
Patient samples. For WES and WGS, fresh-frozen tumor and matched germline
control specimens were obtained from adult patients diagnosed with chordoma
according to World Health Organization criteria at four German cancer centers
(NCT Heidelberg and Heidelberg University Hospital, Heidelberg; West German
Cancer Center, Essen; University Hospital Carl Gustav Carus, Dresden; Frankfurt
University Hospital, Frankfurt). Disease manifestations and previous treatments
are given in Supplementary Table 1. Prior to processing, samples were pseudo-
nymized, and histology and cellularity of the tumors were determined at the
Institute of Pathology, Heidelberg University Hospital. All patients provided
written informed consent under a protocol approved by the Ethics Committee
of Heidelberg University, and the study was conducted in accordance with the
Declaration of Helsinki.
Isolation of analytes. DNA from tumor and control specimens was extracted
at the DKFZ-HIPO Sample Processing Laboratory using the AllPrep DNA/RNA/
Protein Mini Kit (Qiagen). DNA quality was assessed with a 2100 Bioanalyzer
system (Agilent), and DNA quantification was performed using a Qubit 2.0
Fluorometer (Invitrogen).
WES. SureSelect Human All Exon in-solution capture reagents (Agilent) were used
for exome capturing. The specific versions of the target captures used for the
different samples are given in Supplementary Table 2. Briefly, 1.5 μg genomic DNA
was fragmented to 150–200 base pairs (bp) insert size with a Covaris S2 device,
and 250 ng of Illumina adapter-containing libraries were hybridized with exome
baits at 65 °C for 16 h. Paired-end sequencing (2 × 101 bp) was carried out with
a HiSeq 2500 instrument (Illumina) for samples Chord_01, Chord_02, Chord_03,
Chord_04, and Chord_07 and with a HiSeq 4000 instrument (Illumina) for
samples Chord_05, Chord_06, Chord_08 and Chord_09.
WGS. Library preparation was performed with the TruSeq Nano Library
Preparation Kit (Illumina). A HiSeq X instrument (Illumina) was used for paired-
end sequencing (2 × 151 bp).
Mapping of sequencing data. Read mapping was performed using the 1000
Genomes Phase 2 assembly of the Genome Reference Consortium human genome
(build 37, version hs37d5) concatenated with the genome of Enterobacteria phage
phiX174 using BWA mem (version 0.7.15; parameter -T 0 and all other parameters
set to default). BAM files were sorted with bamsort (part of the package bio-
bambam, version 0.0.148), and duplicates were marked with markdup (part of the
package Sambamba, version 0.6.5)31. Sequencing coverage and quality scores can
be found in Supplementary Table 2.
Detection of SNVs and small indels. An in-house computational analysis pipe-
line derived from SAMtools mpileup and bcftools was used for detection of somatic
SNVs from paired tumor and control specimens. Adjustments of parameters and
heuristic filtering were performed as described previously32–34. For determining
germline and somatic variants, a pileup of the bases in the paired control specimen
was computed for each SNV position by SAMtools mpileup with parameters -Q 0 -
q 1. After annotation with GENCODE (release 19) using ANNOVAR (version
November 2014), somatic non-synonymous coding variants of high confidence
were selected. The analysis of mutational signatures was based on all high-
confidence somatic variants. Small indels were identified by Platypus (version 0.8.1;
parameters ploidy= 2, nIndividuals= 2) by providing matched tumor and control
BAM files35. To be considered as high-confidence, somatic calls (control genotype
0/0) were required to either have the Platypus filter flag PASS or pass custom filters
allowing for low variant frequency using a scoring scheme. Indels were annotated
with ANNOVAR (version February 2016), and somatic high-confidence indels
falling into a coding sequence or splice site were extracted.
Supervised analysis of mutational signatures. For linear combination decom-
position of individual mutational catalogs with known mutational signatures
(http://cancer.sanger.ac.uk/cosmic/signatures), non-negative least squares (NNLS)
were computed using the R package YAPSA (Yet Another Package for Signature
Analysis)36,37. Mutational catalog correction was performed to account for dif-
ferences in the occurrence of triplet motifs by comparing the whole genome to
WES capture regions (function normalizeMotifs_otherRownames in YAPSA). In
order to improve specificity, the NNLS computation was performed twice. Only
signatures with exposures, i.e., contributions in the linear combination, reaching a
certain cut-off were kept after the first execution, and the NNLS algorithm was
repeated with the reduced set of signatures. Since the detection of signatures may
differ, a random operator characteristic analysis was performed to determine
signature-specific cut-offs using the mutational catalogs of 7042 tumor samples
(WGS, n= 507; WES, n= 6,535)17 and mutational signatures from COSMIC:
AC1: 0; AC2: 0.0104594; AC3: 0.0819406; AC4: 0.0175397; AC5: 0; AC6:
0.0015485; AC7: 0.040133; AC8: 0.242755; AC9: 0.1151714; AC10: 0.0100838;
AC11: 0.0992488; AC12: 0.2106201; AC13: 0.0078766; AC14: 0.1443059; AC15:
0.0379603; AC16: 0.3674349; AC17: 0.002648; AC18: 0.3325386; AC19: 0.1156454;
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AC20: 0.1235028; AC21: 0.1640255; AC22: 0.0310222; AC23: 0.0333866; AC24:
0.0324018; AC25: 0.0161191; AC26: 0.0933522; AC27: 0.0093201; AC28:
0.0561643; AC29: 0.0593621; AC30: 0.0591536. The specific cut-offs can also be
retrieved from YAPSA with the following R code: library(YAPSA), data(cut-offs),
cutoffCosmicValid_rel_df[6,]. Confidence intervals were determined by using
the concept of profile likelihoods38. Likelihoods were assessed from the residue
distribution after NNLS decomposition (initial model of the data). The confidence
interval of a given signature was determined as follows: the exposure to this sig-
nature was perturbed and fixed as compared to the initial model. The exposures to
remaining signatures were again computed using the NNLS algorithm, resulting in
an alternative model with one degree of freedom less. Likelihoods were then
computed from the distribution of residuals of the alternative model. Next, a
likelihood ratio test for the log-likelihoods of the initial and alternative models
was performed, yielding a test statistic and a P value for the perturbation. To
determine the limits of 95% confidence intervals, the Gauss-Newton method-
based R package pracma was used for computing perturbations corresponding
to P values of 0.05/2= 0.025 (two-sided). Mutational signatures derived from
chordoma cases were compared to mutational signatures derived from a back-
ground of cancer specimens (WGS, n= 507; WES, n= 6,535)17 by Fisher exact
tests and subsequent multiple testing correction using the Benjamini-Hochberg
method.
Look-up analysis of variant allele fractions. The sets of mutations detected in
patient Chord_05 before and after olaparib treatment were merged, and a look-up
of read counts for the reference and alternative alleles was performed with Platypus
(version 0.8.1.1; option callVariants). All variants with a minimum coverage of 20
in both samples were kept for further analysis. The output of Platypus was read
into R and parsed for the read counts, germline mutations were removed, and
variant allele fractions were displayed in a scatter plot.
Analysis of copy numbers, tumor cell content, and ploidy. ACEseq39 was used
for calling allele-specific copy number alterations (CNAs) from WGS data.
Absolute allele-specific copy numbers, tumor cell content (TCC), and ploidy were
determined by computing coverage ratios of tumor and control as well as the B
allele frequency (BAF) of heterozygous single-nucleotide polymorphisms (SNPs).
Structural variants called with SOPHIA were included to enable better genome
segmentation. To prevent biases due to oversegmentation, copy number profiles
were further smoothed prior to calculating the total number of gains and losses.
Segments smaller than 3 Mbp were merged with the neighboring segment to which
they had the smallest difference between respective total copy number values.
Based on the resulting segments, the number of gains and losses was estimated.
CNAs were inferred from WES data with cnvKit (version 0.9.3) using default
parameters. SNPs were determined as heterozygous if the alternative allele fraction
ranged between 0.3 and 0.7 in the paired normal control. Segments covering at
least 20 heterozygous SNPs were used to infer TCC, ploidy, and allele-specific copy
number estimates. Segments were categorized as balanced or imbalanced based on
the distribution of alternative SNP allele frequencies. A segment was classified as
balanced if the global maximum of the distribution ranged between 0.45 and 0.55.
Remaining segments were categorized into two groups, ambiguous segments
containing one density peak outside the 0.45–0.55 interval, and imbalanced
segments containing two peaks. Ambiguous segments were subsequently neglected.
The mean BAF of all SNPs in the segment that were heterozygous in the germline
was calculated for imbalanced segments using the allele with the higher read count
as B allele. The mean B allele read count was computed as the product of the total
coverage and the BAF of the respective segment.
An adapted ACEseq method was used for TCC and ploidy estimation of a
sample. To estimate TCC, values of 0.15–1.0 were tested, and a range of 1.0–6.5 was
allowed for estimation of ploidy. A segment-wise estimation40 of absolute and
allele-specific copy numbers as well as the decrease in heterozygosity (DH) were
computed for every possible TCC and ploidy combination. For balanced segments,
allele-specific copy numbers were computed as total copy number divided by two.
For imbalanced segments, a function of coverage and B allele read counts was
applied. For calculation of total and allele-specific copy numbers, the weighted
mean distance of all segments to the next allowed integer copy number state was
computed, where allowed means even total copy number states for balanced
segments and any integer copy number state for imbalanced segments and allele-
specific copy numbers. TCC/ploidy combinations with negative copy number states
or a DH above one for any segment were excluded. Local minima in the weighted
mean distance were considered as possible TCC/ploidy solution for the sample and
were visually inspected. In addition, TCC was determined from the mutant allele
fraction distribution for somatic SNVs, and CNA- and SNV-based estimates were
compared. For sample Chord_07, TCC was manually adjusted to 20%.
HR deficiency and LST scores. For estimating stable HRD and LST scores,
oversegmentation caused by technical noise was reduced by smoothing of copy
number profiles. Segments smaller than 3 Mbp were merged with their more
similar neighbor as previously described18. Any switch between copy number states
of segments larger than 10 Mbp that did not correspond to entire chromosome
arms was counted as LST18. Additionally, subchromosomal segments larger than
15 Mbp and corresponding to loss of heterozygosity were counted for the HRD
estimation.
Energy calculations. Calculations were carried out considering both the con-
stitutively active PARP1 structure (Protein Data Bank Identifier [PDB ID]: 5DS3)
and the region corresponding to the ART domain and the HD (i.e. amino acids
662–1011) of the PARP1-DNA complex structure (PDB ID: 4DQY)23,41. Structures
were pre-minimized to solve potential clashes using the Rosetta Relax protocol42,
applying backbone restraints to avoid excessive displacements from the starting
X-ray structures. Fifty energy calculation cycles were performed in low-resolution
(i.e., with a fixed backbone) and high-resolution (i.e., allowing backbone degrees of
freedom) modes using the Rosetta ddG_monomer protocol25, and ddG values are
expressed as REU. Since the same positive ddG trend was observed in all simu-
lations, results are shown only for the low-resolution mode, which gave the highest
ddG values. To detect amino acids perturbed by the p.T910A mutation, side chain
conformations were compared between the top-scoring mutant and wild-type
conformations generated during the low-resolution simulations, and amino acids
with at least one side-chain atom displacement greater than 0.05 Ǻ were selected
employing ad hoc created biopython scripts43. Structure representations were
drawn with PyMOL 1.7.x (https://pymol.org).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequencing data were deposited in the European Genome-phenome Archive under
accession code EGAS00001002720 [https://www.ebi.ac.uk/ega/studies/EGAS00001002720].
Code availability
All code used is available upon request.
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